Research Needs in Pompe Disease: Barry Byrne, MD, PhD


The director of the Powell Gene Therapy Center at the University of Florida discussed unmet needs that remain in Pompe disease.

“An ongoing challenge is to get these registries and natural history data sets to be robust and reliable. But that's something that I think a lot of people in this community of rare disease patients understand. It's invaluable for them to participate.”

While international Rare Disease Day has come and gone, there is still more work that needs to be done in improving awareness and addressing unmet needs in rare diseases such as Pompe disease.

Gene and cell therapies are being investigated as a single-dose alternative to enzyme replacement therapy. Current studies investigating gene therapies in this space include the phase 1/2 RESOLUTE study (NCT04093349) of SPK-3006 as well multiple studies from the University of Florida’s Powell Center for Gene Therapy.

CGTLive spoke with Barry Byrne, MD, PhD, director, Powell Center for Gene Therapy, University of Florida, and advisory committee member, Muscular Dystrophy Association, about unmet needs in Pompe disease. He discussed further research that he would like to see conducted within the space, including natural history studies.

Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
© 2024 MJH Life Sciences

All rights reserved.